A phase II study of the dolastatin 15 analogue LU 103793 in the treatment of advanced non-small-cell lung cancer

Randolph S. Marks, David L. Graham, Jeff A. Sloan, Shauna Hillman, Steven Fishkoff, James E. Krook, Scott H. Okuno, James A. Mailliard, Tom R. Fitch, Ferdinand Addo

Research output: Contribution to journalArticle

37 Scopus citations

Abstract

A phase II study of the dolastatin 15 analog LU 103793 was conducted by the North Central Cancer Treatment Group in patients with advanced non-small-cell lung cancer (SCLC). Previously untreated patients received this agent at a dosage of 2.5 mg/m2 as a 5-minute intravenous infusion for 5 consecutive days every 3 weeks. Between September 1997 and July 1998, 17 patients were accrued in this study. Forty-two treatment cycles were administered with relatively modest toxicity. No responses were seen. This agent appears to be inactive in the treatment of advanced non-SCLC.

Original languageEnglish (US)
Pages (from-to)336-337
Number of pages2
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume26
Issue number4
DOIs
StatePublished - Aug 2003

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A phase II study of the dolastatin 15 analogue LU 103793 in the treatment of advanced non-small-cell lung cancer'. Together they form a unique fingerprint.

  • Cite this